Home

Pfizer (PFE)

25.31
-0.37 (-1.45%)
NYSE · Last Trade: Oct 9th, 2:35 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Investors Brace for Pullback as Short-Bias ETF Inflows Signal Growing Bearishness
A significant surge in capital flowing into short-bias Exchange-Traded Funds (ETFs) has sent a clear signal through the financial markets: investor sentiment is shifting towards caution and a potential stock market pullback. This notable trend, particularly pronounced in recent weeks, suggests that a growing number of investors are actively positioning
Via MarketMinute · October 9, 2025
Why Shares in Viking Therapeutics Surged This Weekfool.com
The small-cap pharmaceutical company may be the next in line as takeover fever heats up.
Via The Motley Fool · October 9, 2025
Market Giants Retreat: S&P 500 and Nasdaq Pull Back from Record Highs Amidst Economic Headwinds
The relentless ascent of the U.S. stock market has hit a significant speed bump, as both the S&P 500 and Nasdaq Composite have retreated from their recent record highs. This pullback, occurring after weeks of robust gains, signals a period of reassessment for investors grappling with a confluence
Via MarketMinute · October 9, 2025
Most active S&P500 stocks in Thursday's sessionchartmill.com
Looking for the most active stocks in the S&P500 index on Thursday? Dive into today's session and discover the stocks that are dominating the trading activity and setting the pace for the market.
Via Chartmill · October 9, 2025
Wilsey Discloses $2.9 Million Purchase of Pfizer Stock Amid Landmark Trump Dealfool.com
Via The Motley Fool · October 9, 2025
Carolina Wealth Trims It's AbbVie Stake to Nearly Nothingfool.com
Via The Motley Fool · October 9, 2025
5 Healthcare Plays Powering the Sector’s Big Comebackmarketbeat.com
After years of lagging, the healthcare sector is showing signs of a turnaround driven by lower rates, policy clarity, and renewed investor interest.
Via MarketBeat · October 9, 2025
Watch Out Eli Lilly, This Pharma Giant Is Gunning to Be a Top Player in the Obesity Marketfool.com
Roche has a promising GLP-1 drug that is entering phase 3 trials.
Via The Motley Fool · October 9, 2025
What's going on in today's session: S&P500 most active stockschartmill.com
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Wednesday. Discover the stocks that are generating the highest trading volume and driving market activity.
Via Chartmill · October 8, 2025
10 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · October 8, 2025
Why Waters Corporation (WAT) Stock Is Up Today
Shares of scientific instruments company Waters Corporation (NYSE:WAT) jumped 3.2% in the morning session after Rothschild & Co initiated coverage on the stock with a 'Buy' rating and a $390 price target. 
Via StockStory · October 8, 2025
Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook
Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by the company's recent strategic guidance, which forecasts over $5 billion in potential annual peak sales from its robust pipeline of
Via MarketMinute · October 8, 2025
U.S. Government Shutdown Deepens Economic Uncertainty, Airports Face Mounting Strain
Washington D.C., October 8, 2025 – The U.S. federal government remains in the throes of a shutdown, now entering its second week, as lawmakers in Washington continue to grapple with a stalemate over federal funding for Fiscal Year 2026. This ongoing budgetary impasse, which commenced on October 1, 2025,
Via MarketMinute · October 8, 2025
Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Aheadfool.com
These biotechs could finally come into their own by the end of the decade.
Via The Motley Fool · October 8, 2025
Why AbbVie and Johnson & Johnson Could Outperform Pfizermarketbeat.com
Pfizer stock is moving higher after being named part of the TrumpRx platform; but two other biopharma companies may offer better long-term growth potential
Via MarketBeat · October 8, 2025
Eli Lilly Stock Eases After-Hours: Ex-FDA Official Ejected By RFK Jr. Joins Firm — Will Investors Warm Up?stocktwits.com
Investors reacted to the company’s leadership shake-up and new data from its ulcerative colitis therapy Omvoh showing sustained remission over four years.
Via Stocktwits · October 7, 2025
Curious about the most active S&P500 stocks in today's session?chartmill.com
Explore the S&P500 index on Tuesday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest.
Via Chartmill · October 7, 2025
Why QuidelOrtho (QDEL) Stock Is Down Today
Shares of healthcare diagnostics company QuidelOrtho (NASDAQ:QDEL) fell 4.4% in the morning session after Citigroup analyst Patrick Donnelly downgraded the stock to 'Neutral' from 'Buy' and lowered the price target. The firm cut its price projection for QuidelOrtho to $33 from $40, a reduction of 17.5%. This adjustment by Citigroup reflected a change in the firm's outlook on the company's stock performance. The downgrade and price target cut highlighted concerns about QuidelOrtho's near-term growth prospects.
Via StockStory · October 7, 2025
The No. 1 Investing Mistake to Avoid As Washington Grinds to a Haltfool.com
Washington has shut down -- but don't fall into a panic, because these things don't last.
Via The Motley Fool · October 7, 2025
Down 50%, Should You Buy the Dip on Pfizer?fool.com
Pfizer's stock price is down materially from its 2021 highs, but it is also up notably from its April 2025 lows.
Via The Motley Fool · October 7, 2025
Why The Pfizer-Trump Pharma Deal Is A Win For Branded Pharma, But Not For Consumerstalkmarkets.com
The deal on drug prices between the US Administration and Pfizer will leave the margins of innovative pharma companies intact.
Via Talk Markets · October 7, 2025
TrumpRx Brings Pfizer Into the Green—Is It a Buy?marketbeat.com
Pfizer entered into a major agreement with the U.S. government to produce more affordable drugs for Americans. However, the stock’s outlook is still cloudy.
Via MarketBeat · October 7, 2025
Worried About Tariffs? 2 Safe Haven Stocks to Buy on the Dip With $500fool.com
Tariffs aren't likely to weigh on growth at these companies.
Via The Motley Fool · October 7, 2025
Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Dealmarketbeat.com
Eli Lilly just got great news, courtesy of Pfizer and Trump, leading shares to their highest level in five months. Its rally may just be getting started.
Via MarketBeat · October 6, 2025
U.S. Labor Market Stalls: Moody's Reports 'Essentially No Job Growth' Amidst Government Shutdown, Raising Recession Fears
Washington D.C., October 6, 2025 – The American labor market appears to have hit a significant speed bump, with Moody's Analytics reporting "essentially no job growth" for the U.S. in September 2025. This concerning assessment comes at a critical juncture for the economy, compounded by an ongoing federal government
Via MarketMinute · October 6, 2025